1. Home
  2. ELTX vs KOSS Comparison

ELTX vs KOSS Comparison

Compare ELTX & KOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Elicio Therapeutics Inc.

ELTX

Elicio Therapeutics Inc.

HOLD

Current Price

$2.36

Market Cap

63.3M

Sector

Health Care

ML Signal

HOLD

Logo Koss Corporation

KOSS

Koss Corporation

HOLD

Current Price

$3.55

Market Cap

36.5M

ML Signal

HOLD

Company Overview

Basic Information
Metric
ELTX
KOSS
Founded
2011
1953
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Consumer Electronics/Appliances
Sector
Health Care
Consumer Staples
Exchange
Nasdaq
Nasdaq
Market Cap
63.3M
36.5M
IPO Year
2014
1994

Fundamental Metrics

Financial Performance
Metric
ELTX
KOSS
Price
$2.36
$3.55
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$18.00
N/A
AVG Volume (30 Days)
261.7K
14.0K
Earning Date
05-12-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
39.29
55.56
EPS
N/A
N/A
Revenue
$2,301,000.00
$13,020,773.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
3.14
52 Week Low
$2.36
$3.37
52 Week High
$16.00
$5.91

Technical Indicators

Market Signals
Indicator
ELTX
KOSS
Relative Strength Index (RSI) 26.74 46.18
Support Level N/A N/A
Resistance Level $3.32 $4.10
Average True Range (ATR) 0.14 0.15
MACD -0.02 0.01
Stochastic Oscillator 3.43 55.12

Price Performance

Historical Comparison
ELTX
KOSS

About ELTX Elicio Therapeutics Inc.

Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.

About KOSS Koss Corporation

Koss Corp is engaged in the design, manufacture, and sale of stereo headphones and related accessory products. It operates in the audio/video industry segment of the home entertainment industry. The company markets a line of headphones, wireless Bluetooth headphones, wireless Bluetooth speakers, computer headsets, telecommunications headsets, and active noise-canceling headphones. The majority of the firm's revenue is derived from sales of stereo headphones. The Company also sells products to distributors for resale to school systems, and directly to other manufacturers for inclusion with their own products.

Share on Social Networks: